Preclinical studies suggest that mTOR inhibitors (e.g., rapamycin, RAD001), combined with standard therapies, reduce tumor burden and prolong survival in HPV-associated cancers (Molinolo et al., 2012). Here, MTOR is linked to neoplasm.